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Abstract Peracetylated N-a-azidoacetylmannosamine
(Ac4ManNAz) is metabolized by cells to CMP-azidosialic
acid. It has been demonstrated previously that in this way
azidosialic acid-containing glycoproteins are formed that
can be labeled on the cell surface by a modified Staudinger
ligation. Here, we first demonstrate that the same proce-
dure also results in the formation of azidosialic acid-contain-
ing gangliosides. Deoxymannojirimycin, an inhibitor of
N-glycan processing in proteins, decreases the total cell
surface labeling in Jurkat cells by ?25%. Inhibition of gan-
glioside biosynthesis with N-[5-(adamantan-1-yl-methoxy)-
pentyl]1-deoxynojirimycin reduces cell surface labeling by
?75%. In conclusion, exposure of cells to Ac4ManNAz
allows in vivo chemical tagging of gangliosides.—Bussink,
A. P., P. F. van Swieten, K. Ghauharali, S. Scheij, M. van Eijk,
T. Wennekes, G. A. van der Marel, R. G. Boot, J. M. F.
G. Aerts, and H. S. Overkleeft. N-Azidoacetylmannosamine-
mediated chemical tagging of gangliosides. J. Lipid Res. 2007.
48: 1417–1421.
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Glycoconjugate-metabolizing glycosyltransferases and
glycosidases have become important drug targets in re-
cent years. Nature provides numerous lead compounds,
primarily polyhydroxylated alkaloids (denominated imi-
nosugars), that exert important biological activities by
inhibiting specific glycosidases (1, 2). Effective therapeutic
strategies based on interfering with glycoprocessing en-
zymes have been described. Two iminosugar-based drugs
are now used in the clinic. Miglitol (N-hydroxyethyldeoxy-
nojirimycin), inhibiting the intestinal glycosidases su-
crase and maltase, is used for the treatment of diabetes
mellitus type II (3). Miglustat (N-butyldeoxynojirimycin),
inhibiting the glycosyltransferase glucosylceramide synth-
ase, is in use for the treatment of Gaucher disease (4–6).
Glucosylceramide synthase, the transferase responsible for
the assembly of glucosylceramide from UDP-glucose and
ceramide, is a key enzyme in the biosynthesis of neutral
glycosphingolipids and sialic acid-containing gangliosides.
More recently, the reduction of ganglioside levels was iden-
tified as a therapeutic approach for diabetes mellitus type
II (7–9). Partial inhibition of glucosylceramide synthase,
therefore, also appears as an attractive therapeutic tar-
get for the prevention and treatment of diabetes mellitus
type II.
As part of our efforts to obtain effective glucosylcer-
amide synthase inhibitors, we searched for a means to
monitor the inhibitory effect of selected iminosugars on
ganglioside biosynthesis in living cells. Bertozzi and co-
workers (10–13) earlier developed a strategy for in vivo
labeling of cell surface glycoproteins. Their approach is
based on the finding that N-a-azidoacetylmannosamine is
accepted by the CMP-sialic acid biosynthesis machinery.
The resulting CMP-azidosialic acid in turn is recognized by
sialic acid transferases, leading to the biosynthesis and cell
surface expression of azidosialic acid containing N-linked
glycoproteins. The azide can next be chemoselectively
tagged by a modified Staudinger ligation. To promote the
formation of azidosialic acid, Saxon and Bertozzi (10) es-
tablished that peracetylated N-a-azidoacetylmannosamine
(Ac4ManNAz) is vividly taken up by cells and efficiently
metabolized to N-a-azidoacetylmannosamine by cytosolic
esterases. The realization that gangliosides, like GM3, also
contain a sialic acid residue at the nonreducing end led
us to explore whether the strategy developed by Saxon
and Bertozzi (10) would also have merit in cell surface
labeling of gangliosides. Here, we demonstrate the va-
lidity of this with the finding that Jurkat cells cultured
in the presence of Ac4ManNAz express azidosialic acid-
containing glycosphingolipids at levels at least as high as
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those of azidosialic acid-containing N-linked glycopro-
teins. We further show that cell surface labeling of azido-
sialic acid-containing glycoproteins and gangliosides can
be suppressed independently by the proper selection of
iminosugars: those that inhibit N-linked glycan processing




Peracetylated N-azidoacetylmannosamine was synthesized as
described previously (11). Phosphine-biotin was synthesized as
described (14). N-[5-(Adamantan-1-yl-methoxy)-pentyl]1-deoxy-
nojirimycin was synthesized as reported (15). All other chemical
solvents and reagents were of analytical grade, obtained from
commercial suppliers, and used without further purification
unless stated otherwise.
Cell culture conditions
Jurkat cells were grown and maintained in RPMI 1640 medium
with 2 mM L-glutamine (Biowhittaker, Baltimore, MD) contain-
ing 10% fetal calf serum (Gibco, Carlsbad, CA) at 5% CO2. Cells
were seeded at ?1.5 3 105 ml in 5 ml flasks for flow cytometry or
50 ml flasks for lipid analysis. Cell viability was assessed during
maintenance and before and after the various stages of labeling
using trypan blue dye exclusion.
Both peracetylated N-azidoacetylmannosamine and N-[5-
(adamantan-1-yl-methoxy)-pentyl]1-deoxynojirimycin were
added to cell cultures from stock solutions in DMSO. The final
concentration of DMSO in the culture medium was 1% (v/v).
Deoxymannojirimycin (DMM; Sigma-Aldrich, Nieuwegein, The
Netherlands) was added from stock solution in ethanol. As nega-
tive controls, equal volumes of the appropriate solvent were
added to the cell culture.
Labeling of cell surface azides
After 3 days of incubation in the presence of 50 mM per-
acetylated N-azidoacetylmannosamine, cells were collected by
centrifugation at 1,500 rpm for 10 min, washed three times in
cold PBS, and resuspended in PBS containing 2% (v/v) fetal calf
serum. The cells were distributed on a six-well plate in 1 ml, after
which an equal amount of 0.5 mM biotin-phosphine in PBS was
added. After incubation at room temperature for 3 h under mild
shaking, the cells were collected by centrifugation and washed
three times in cold PBS. Either the cells were labeled with
streptavidin-FITC for the purpose of flow cytometry or total lipids
were isolated as described below. FITC labeling was accom-
plished by incubation of cells with 1 ml of 1:1,000 streptavidin-
FITC (Gibco) in PBS for 1 h in the dark at 4jC, after which the
cells were washed three times in cold PBS. Flow cytometry was
performed using a FACSscan (Becton Dickinson, Palo Alto, CA)
with settings optimized for FITC fluorescence.
Isolation of gangliosides and ganglioside ligation product
Lipids were extracted with chloroform-methanol (1:1, v/v),
and phase separation was performed according to Bligh and Dyer
(16). The aqueous phase was evaporated to dryness under N2.
The samples were desalted on a SPE C18 column (Bakerbond,
Deventer, The Netherlands). In short, the dried fractions were
dissolved in 1 ml of water containing 0.1 M NaCl (pH 4.5). The
solution was applied to the column, which had been preequili-
brated with 2 ml of the same watery solution. Subsequently, the
column was desalted with 30 ml of water, after which the lipids
were eluted with 20 ml of a mixture containing equal volumes of
chloroform and methanol. The eluent was evaporated to dryness
under N2.
In vitro Staudinger ligation of metabolically
labeled gangliosides
Desalted gangliosides were dissolved in 500 ml of a mixture
of equal volumes of chloroform and methanol containing
phosphine-biotin in a final concentration of 1 mM. Next,
100 ml of water was added, and the reaction was allowed to
proceed overnight at room temperature under mild stirring,
after which the organic solvents and the water were evaporated to
dryness under N2.
Ganglioside detection
Gangliosides were detected by analysis of the acidic glyco-
lipid fraction obtained after Folch extraction using chloroform-
methanol-water (65:25:4) as a solvent (17). Gangliosides were
quantified after the release of oligosaccharides from glyco-
sphingolipids by ceramide glycanase detection (18). The oli-
gosaccharides were labeled at their reducing end with
the fluorescent compound anthranilic acid (2-aminobenzoic
acid) before analysis using normal-phase high-performance liq-
uid chromatography.
Glucosylceramide synthase activity in living cells was deter-
mined using as substrate fluorescently labeled 6-[(7-nitrobenz-2-
oxa-1,3-diazol-4-yl)amino]hexanoyl-sphingosine(C6-NBD-cera-
mide) (19). Briefly, cells were incubated with 150 mM lipid and
harvested at different time points. Lipids were extracted and
separated by thin-layer chromatography, and NBD-ceramide
and NBD-glucosylceramide were quantified (19). Endogenous
cell surface GM3 was visualized by flow cytometry using mono-
clonal anti-GM3 antibody (Seikagu, Tokyo, Japan) and FITC-
conjugated secondary antibodies according to the procedure
described previously (20).
RESULTS
Cell surface labeling of azidosialosides
Jurkat cells were cultured for 3 days in medium con-
taining 50 mM Ac4ManNAz. Labeling of cell surface azido-
sialosides was performed as described in Materials and
Methods. Cells were harvested and washed in labeling
buffer and labeled for 3 h with phosphine-biotin. Next,
cells were incubated with streptavidin-FITC, washed, and
resuspended for flow cytometry analysis. Intense labeling
of the cell surface was obtained by this procedure. The
presence of Ac4ManNAz did not influence the rate of cell
proliferation. Cell viability, as assessed by trypan blue ex-
clusion, was not affected by the procedure. Very similar
results were obtained with murine B16 melanoma cells cul-
tured in DMEM containing 10% fetal calf serum, 100 U/ml
penicillin, and 0.1 mg/ml streptomycin at 10% CO2 (data
not shown).
Distinction of azide-containing N-linked glycoproteins
and gangliosides
To distinguish between the presence of azide moieties
in N-linked glycoproteins and gangliosides, cells were
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cultured in the presence or absence of 1 mM DMM and
10 mM N-[5-(adamantan-1-yl-methoxy)-pentyl]1-deoxyno-
jirimycin (AMP-DNM). DMM specifically inhibits the pro-
cessing of high-mannose-type N-linked glycan to sialic
acid-containing complex-type structures. We demonstrated
previously that 1 mM DMM prevents the formation of
complex-type glycan in glycoproteins in various cell types
(21). Using radioactive motioning labeling, we observed
that the presence of 1 mM DMM in the culture medium of
Jurkat cells also completely blocked the conversion of
EndoH-sensitive glycan to resistant structures in newly
formed glucocerebrosidase molecules, indicating effec-
tive inhibition of glycan processing (data not shown). The
presence of 1 mM DMM in the culture medium did not
reduce the cell surface concentration of the ganglioside
GM3, as detected by flow cytometry using antibody di-
rected to the ganglioside.
AMP-DNM specifically inhibits the first step in glyco-
sphingolipid biosynthesis catalyzed by glucosylceramide
synthase (IC50 ? 150 nM). Incubation of Jurkat cells with
10 mM AMP-DNM also completely inhibits in these cells
the conversion of C6-NBD-ceramide to C6-NBD-glucosyl-
ceramide and subsequent glycosphingolipids (Fig. 1). We
also observed by flow cytometry analysis that after 3 days of
culture of Jurkat cells in the presence of 10 mM AMP-DNM,
cell surface ganglioside GM3 is reduced by 80% (data not
shown). AMP-DNM is known not to interfere with glyco-
protein biosynthesis and processing (22).
Culturing of Jurkat cells for 3 days in the presence of
1 mM DMM and 0.05 mM Ac4ManNAz resulted in a
24.0% reduction of fluorescent cell surface labeling
(Fig. 2). In a second independent experiment, the reduc-
tion of fluorescence by DMM was 27%. The presence of
10 mM AMP-DNM led to an 86.5% reduction of fluores-
cence (Fig. 2). In the second independent experiment, the
reduction of fluorescence by AMP-DNM was 68%. The com-
bined presence of DMM and AMP-DNM led to an almost
complete (95%) loss of fluorescence in all experiments. Very
similar observations were made with murine melanoma cells
(data not shown). Our findings suggest that a very large
proportion of the cell surface azidosialosides in Jurkat cells
are found in sialic acid-containing glycosphingolipids.
Demonstration of the formation of azidoGM3
To further substantiate that azidogangliosides are in-
deed formed in Jurkat cells exposed to Ac4ManNAz, we
isolated gangliosides and analyzed their oligosaccharides
released by ceramide glycanase treatment and fluorescent
labeling with anthranilic acid (AA). In Jurkat cells, the
gangliosides almost exclusively consist of GM3 molecules.
Figure 3 shows that two trisaccharides derived from GM3
were detected. The retention time of the first peak coin-
cides with the normal sialic acid-galactose-glucose-AA
generated from GM3. Incubation with phosphine reagent
did not influence its chromatographic behavior. The sec-
ond peak shifted in its retention time after incubation with
the phosphine reagent, indicating that it indeed contains
an azide moiety.
Fig. 1. Inhibition of glucosylceramide synthesis in Jurkat cells by
N-[5-(adamantan-1-yl-methoxy)-pentyl]1-deoxynojirimycin (AMP-
DNM). Jurkat cells were incubated for 1 h with 6-[(7-nitrobenz-2-
oxa-1,3-diazol-4-yl)amino]hexanoyl-sphingosine (C6-NBD-ceramide)
(Cer), and the formation of C6-NBD-glucosylceramide (GlcCer)
and C6-NBD-sphingomyelin (SM) after 4 h was monitored as de-
scribed in Materials and Methods. Lysosomal degradation of C6-
NBD-glucosylceramide was prevented by the presence of 1 mM
conduritol B-epoxide. Cells were exposed during incubation and
chase with the indicated amounts of AMP-DNM. Cellular NBD-
sphingolipid is put at 100%. Error bars represent 6 SD.
Fig. 2. Cell surface labeling of cells cultured with peracetylated
N-a-azidoacetylmannosamine (Ac4ManNAz) in the absence or
presence of deoxymannojirimycin (DMM) and AMP-DNM. Jurkat
cells were labeled with Ac4ManNAz and incubated with phosphine-
biotin and then streptavidin-FITC, as described in Materials and
Methods. Cell surface labeling was determined by FACSscan. A:
Example of the effect of AMP-DNM. Overlay histogram showing
labeled cells cultured in the absence of AMP-DNM, on the right,
and the downward shift in cells cultured with 10 mM AMP-DNM
(dotted), in the middle. Cells cultured in absence of Ac4ManNAz
but exposed to the Staudinger reagent are shown on the left. Note
the log scale on the x axis. B: Overview of the impact of AMP-DNM
(10 mM) and DMM (1 mM) on the labeling of Jurkat cells cultured
in the presence of Ac4ManNAz.
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Our study reveals that exposure of Jurkat cells to
Ac4ManNAz results in the formation of chemically tagged
ganglioside, in particular the most abundant ganglioside,
GM3. The proportion of azidoGM3 is ?60% of total GM3,
suggesting a very efficient incorporation of azidosialic acid
in gangliosides. This is not entirely surprising, because
different forms of sialic acid occur in nature, species that
are either acylated or glycolated at the N atom. Apparently,
the azide group modification in sialic acid is equally well
tolerated by the ganglioside biosynthetic machinery. It is
of interest that the proportion of cell surface-tagged gly-
coproteins is actually lower than that of gangliosides.
Again, this is not entirely surprising if one considers the
estimated ratio of ganglioside to glycoprotein molecules at
the cell surface. Gangliosides are largely located at the cell
surface. Because nearly all ganglioside is GM3 in Jurkat
cells, these cells contain per gram wet weight ?200 nmol
of sialic acid associated with glycolipid. Assuming that
?1% of all cellular protein is cell membrane glycoprotein
with an average mass of 50 kDa, Jurkat cells would contain
?20 nmol of glycoprotein per gram wet weight. To explain
the observed ratio (3:1) of FITC-labeled ganglioside to
glycoprotein, it would require on average at least three
sialic acids per membrane glycoprotein.
The pioneering work of Bertozzi and colleagues (10–13)
has led to a convenient procedure to chemically tag sialic
acid-containing glycoconjugates that can be subsequently
labeled at the cell surface. Our study reveals that this also
includes gangliosides besides glycoproteins. This ap-
proach may have interesting applications. First, it offers a
novel tool to screen synthetic and natural compounds that
interfere in ganglioside biosynthesis and/or trafficking to
the cell surface. Second, given the postulated role for GM3
in modulating insulin receptor-mediated signaling, it may
be of interest to analyze the impact of various synthetic
tags on this process, which is impaired in type 2 diabe-
tes mellitus.
The authors acknowledge Anneke Strijland and Wilma Donker-
Koopman for their skillful technical assistance and Albert
Groen for useful discussions.
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